Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucinex Full Force Nasal Spray (also marketed as Mucinex Sinus-Max Full Force) is an over-the-counter topical nasal decongestant developed by Reckitt Benckiser. The active ingredient is oxymetazoline hydrochloride (0.05%), a small molecule sympathomimetic amine that acts as an agonist on alpha-adrenergic receptors. By stimulating these receptors in the nasal mucosa, the drug induces vasoconstriction of dilated arterioles, which reduces blood flow and swelling in the nasal passages. It is indicated for the temporary relief of nasal and sinus congestion and pressure associated with the common cold, hay fever, and other upper respiratory allergies. The formulation provides rapid onset of action with effects lasting up to 12 hours and includes a cooling menthol sensation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mucinex Full Force Nasal Spray.